Tuberculosis Elimination and Laboratory Cooperative Agreement

The summary for the Tuberculosis Elimination and Laboratory Cooperative Agreement grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Centers for Disease Control NCHHSTP, which is the U.S. government agency offering this grant.
Tuberculosis Elimination and Laboratory Cooperative Agreement: TB is an airborne disease and globally, a leading cause of death. One fourth of the world's population is infected with TB. In 2017, 10.0 million people around the world became sick with TB disease. There were 1.3 million TB-related deaths world-wide, and TB is the leading killer of people who are HIV infected. A total of 9,105 TB cases (a rate of 2.8 cases per 100,000 persons) were reported in the United States in 2017. This is a 1.6% decrease in the number of cases reported in 2016 and the lowest case count on record in the United States. While the United States continues to make slow progress, current strategies will not, alone, lead to TB elimination in this century. Meeting the U.S. TB elimination goal will require an added focus on testing and treating high-risk persons with latent TB infection (LTBI) to prevent them from developing active TB disease. CDC estimates that up to 13.0 million people in the United States have LTBI and over 80% of U.S. TB cases result from longstanding, untreated LTBI. This NOFO supports the continued focus on identifying and curing persons with TB disease, but also includes the addition of a targeted testing and treatment strategy for LTBI. TB disproportionately affects certain populations, including those who are non-U.S.-born, with HIV infection or diabetes, experiencing homelessness, who are incarcerated, and who use illicit substances. The TB incidence rate among non-U.S.-born persons in 2017 was approximately 15 times greater compared to U.S.-born persons, and the percentage of TB cases occurring in non-U.S.-born persons continues to increase, reaching 70.1% in 2017. Achieving TB elimination in the United States will require focusing on persons in these high-risk groups – an approach that is reinforced by this NOFO. CDC is continuing a 30-year strategy of funding TB programs through cooperative agreements (CoAgs). The primary responsibility for developing and implementing TB P&C and laboratory activities rests with state and local health departments, and this funding is intended to complement those efforts. The intent of this funding is not to supplant or reduce state and local investment in TB control activities and responsibilities (e.g., provision of medications, in-patient care, and health department facilities).
Federal Grant Title: Tuberculosis Elimination and Laboratory Cooperative Agreement
Federal Agency Name: Centers for Disease Control NCHHSTP (HHS-CDC-NCHHSTP)
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: CDC-RFA-PS20-2001
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.116
CFDA Descriptions: Information not provided
Current Application Deadline: September 5th, 2019
Original Application Deadline: September 5th, 2019
Posted Date: July 5th, 2019
Creation Date: July 5th, 2019
Archive Date: October 5th, 2019
Total Program Funding: $0
Maximum Federal Grant Award: $0
Minimum Federal Grant Award: $0
Expected Number of Awards: 61
Cost Sharing or Matching: No
Last Updated: July 5th, 2019
Applicants Eligible for this Grant
State governments - County governments - City or township governments - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility
Competition is limited to 61 project areas, including 50 state public health agencies or their bona fide agents; the cities of Los Angeles, CA; San Francisco, CA; San Diego, CA; Houston, TX; Chicago, IL; New York, NY; Philadelphia, PA; Baltimore, MD; Washington, D.C.; and the territorial governments of Puerto Rico and U.S. Virgin Islands. Eligible applicants with laboratories can apply for laboratory funding.
Grant Announcement Contact
Glenroy Christie
GPC5@cdc.gov
Grants Policy
Similar Government Grants
Accelerating the Prevention and Control of HIV, Viral Hepatitis, STDs and TB in the U.S.-A...
Strengthening Collaboration Between TB Control Programs and Affiliated Partners in the Uni...
Improving Effectiveness of the Tuberculosis Prevention and Control Programs in Resource Li...
Tuberculosis Elimination and Laboratory Cooperative Agreement (CoAg)
World Health Organization: Expanding Efforts and Strategies to Prevent and Control TB Incl...
TB Elimination and Laboratory
Cooperative Agreement to the Medical Research Council (MRC) of South Africa for TB Control...
International Union Against Tuberculosis and Lung Disease (IUATLD): Improving the Effectiv...
More Grants from the Centers for Disease Control NCHHSTP
Strategic Partnerships and Planning to Support Ending the HIV Epidemic in the United State...
The Tuskegee Public Health Ethics Program
National Harm Reduction Technical Assistance and Syringe Services Program (SSP) Monitoring...
Improving Hepatitis B and C Care Cascades: Focus on Increased Testing and Diagnosis
National Center for HIV-AIDS, Viral Hepatitis, STD, and TB Prevention

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2019 FederalGrants.com